Xie Minghong, Zhao Yunlong, Hou Xiaohua, Li Ning, Niu Sha, Xu Xinju
Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People's Hospital, Jiaozuo, China.
Department of Pathology, First Affiliated Hospital of Henan Polytechnic University, Jiaozuo Second People's Hospital, Jiaozuo, Henan, China.
Front Oncol. 2024 Dec 23;14:1476205. doi: 10.3389/fonc.2024.1476205. eCollection 2024.
Pulmonary giant cell carcinoma (PGCC) is a rare subtype of non-small cell lung cancer (NSCLC) characterized by complex pathology, high rates of misdiagnosis or missed diagnosis, an aggressive clinical course, rapid progression, and poor prognosis. This case report describes a 67-year-old Chinese male with a left upper lobe lung mass, diagnosed CT-guided lung biopsy as PGCC with symptomatic multiple cerebral metastases. The tumor showed strong PD-L1 positivity, and genetic testing revealed a TP53 exon 4 c.313G mutation. Treatment involved first-line therapy with Penpulimab injection combined with Anlotinib and concurrent cranial radiotherapy. Significant reduction in both the pulmonary and cerebral metastatic lesions was observed, with notable efficacy. As of June 2024, there has been no disease progression for 26 months, with the patient currently maintained on Anlotinib monotherapy. This case demonstrates the favorable efficacy of Penpulimab injection combined with Anlotinib in treating advanced PGCC. These findings indicate that this combination therapy may offer a promising new therapeutic option for this rare type of lung cancer.
肺巨细胞癌（PGCC）是一种罕见的非小细胞肺癌（NSCLC）亚型，其特点是病理复杂、误诊或漏诊率高、临床过程侵袭性强、进展迅速且预后不良。本病例报告描述了一名67岁的中国男性，其左上肺叶有肿块，经CT引导下肺活检诊断为PGCC并伴有有症状的多发脑转移。肿瘤显示PD-L1强阳性，基因检测发现TP53外显子4 c.313G突变。治疗采用派安普利单抗注射液联合安罗替尼一线治疗并同步进行颅脑放疗。观察到肺部和脑转移病灶均显著缩小，疗效显著。截至2024年6月，患者已26个月无疾病进展，目前维持安罗替尼单药治疗。本病例证明了派安普利单抗注射液联合安罗替尼治疗晚期PGCC的良好疗效。这些发现表明，这种联合治疗可能为这种罕见类型的肺癌提供一种有前景的新治疗选择。
